Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry

Diabetes Research and Clinical Practice

Volumn 90, Issue 3, 2010, Pages 343-351

  Yang, Xilin ^a   So, Wing Yee ^a   Ma, Ronald C W ^a   Yu, Linda W Y ^a   Ko, Gary T C ^a   Kong, Alice P S ^a   Ng, Vanessa W S ^a   Luk, Andrea O Y ^a   Ozaki, Risa ^a   Tong, Peter C Y ^a   Chow, Chun Chung ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer; Glibenclamide; Gliclazide; Sulphonylurea; Type 2 diabetes

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ADULT; ARTICLE; CANCER RISK; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HONG KONG; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE;

EID: 78649480736     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.08.022     Document Type: Article

References (33)

1. Rodriguez C., Patel A.V., Mondul A.M., Jacobs E.J., Thun M.J., Calle E.E. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005, 161(January (2)):147-152.
2. Seow A., Yuan J.M., Koh W.P., Lee H.P., Yu M.C. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J Natl Cancer Inst 2006, 98(January (2)):135-138.
3. Huxley R., Ansary-Moghaddam A., Berrington de Gonzalez A., Barzi F., Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92(June (11)):2076-2083.
4. Inoue M., Iwasaki M., Otani T., Sasazuki S., Noda M., Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006, 166(September (17)):1871-1877.
5. Rousseau M.C., Parent M.E., Pollak M.N., Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006, 118(April (8)):2105-2109.
6. Davila J.A., Morgan R.O., Shaib Y., McGlynn K.A., El-Serag H.B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54(April (4)):533-539.
7. Yang X., So W., Ko G.T., Ma R.C., Kong A.P., Chow C.C., et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008, 179(August (5)):427-437.
8. Yang X., So W.Y., Ma R.C., Ko G.T., Kong A.P., Zhao H., et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2009, 32(October (10)):1826-1832.
9. Yang X., Ko G.T., So W.Y., Ma R.C., Yu L.W., Kong A.P., et al. The associations of hyperglycaemia and insulin usage with the risk of cancer in Type 2 diabetes-the Hong Kong Diabetes Registry. Diabetes 2010, 59(5):1254-1260.
10. Yang X., Zhao H., Sui Y., Ma R.C., So W.Y., Ko G.T., et al. Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 2009, 58(April (7)):1518-1525.
11. Liguori A., Abete P., Hayden J.M., Cacciatore F., Rengo F., Ambrosio G., et al. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 2001, 22(November (22)):2075-2084.
12. Chen J., Mehta J.L. Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease. Curr Hypertens Rep 2006, 8(May (2)):139-143.
13. Monnier L., Colette C., Mas E., Michel F., Cristol J.P., Boegner C., et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010, 53(March (3)):562-571.
14. Sliwinska A., Blasiak J., Drzewoski J. Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells. Chem Biol Interact 2006, 162(September (3)):259-267.
15. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., Evans J.M.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32(September 9):1620-1625.
16. Bowker S.L., Yasui Y., Veugelers P., Johnson J.A. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010, 53(April (8)):1631-1637.
17. Johnson J.A., Gale E.A. Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem?. Diabetes 2010, 59(May (5)):1129-1131.
18. Gerstein H.C. Does insulin therapy promote, reduce, or have a neutral effect on cancers?. JAMA 2010, 303(February (5)):446-447.
19. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29(February (2)):254-258.
20. Monami M., Balzi D., Lamanna C., Barchielli A., Masotti G., Buiatti E., et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007, 23(September (6)):479-484.
21. Sliwinska A., Blasiak J., Kasznicki J., Drzewoski J. In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM). Chem Biol Interact 2008, 173(June (3)):159-165.
22. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol; published ahead of print on December 10, 2008. doi:101007/s00592-008-0083-2.
23. Piwernetz K., Home P.D., Snorgaard O., Antsiferov M., Staehr-Johansen K., Krans M. Monitoring the targets of the St. Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabet Med 1993, 10:371-377.
24. Yang X., So W.Y., Tong P.C., Ma R.C., Kong A.P., Lam C.W., et al. Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med 2008, 168(March (5)):451-457.
25. Ma Y.C., Zuo L., Chen J.H., Luo Q., Yu X.Q., Li Y., et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006, 17(October (10)):2937-2944.
26. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(June (6)):499-502.
27. Yang X., So W.Y., Ma R.C., Ko G.T., Kong A.P., Wang Q., et al. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer 2008, 15(June (2)):597-607.
28. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330(June (7503)):1304-1305.
29. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., Evans J.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32(September (9)):1620-1625.
30. Harrell F. Regression modelling strategies with applications to linear models, logistic regression, and survival analysis 2001, Spinger-Varlag New York, Inc., New York.
31. Joffe M.M., Rosenbaum P.R. Invited commentary: propensity scores. Am J Epidemiol 1999, 150(August (3)):327-333.
32. Stattin P., Bjor O., Ferrari P., Lukanova A., Lenner P., Lindahl B., et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007, 30(March (3)):561-567.
33. Ikeda F., Doi Y., Yonemoto K., Ninomiya T., Kubo M., Shikata K., et al. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 2009, 136(April (3)):1234-1241.